Functional analysis of candidate antigens identified by DNA microarray for highly expression in melanoma

DNA 微阵列鉴定的黑色素瘤高表达候选抗原的功能分析

基本信息

  • 批准号:
    17591185
  • 负责人:
  • 金额:
    $ 2.24万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2005
  • 资助国家:
    日本
  • 起止时间:
    2005 至 2006
  • 项目状态:
    已结题

项目摘要

The identification of molecules that are preferentially expressed in melanoma cells and involved in their malignant phenotypes is important for understanding of melanoma biology and the development of new diagnostic and therapeutic methods. By comparing the expression profile of a melanoma cell line with those of various normal tissues using GeneChip, and by confirming the actual expression of the selected genes by RT-PCR, we identified FABP7,MMA1 and KU-MEL-3. These genes were analyzed for their function by RNA interference and recombinant transduction. By down-regulating the FABP7 expression with FABP7 specific siRNAs, in vitro cell proliferation and Matrigel invasion were suppressed in melanoma cell lines. Over-expression of FABP7 in a FABP7 negative embryonic kidney cell line 293T by transfecting with the FABP7 cDNA, resulted in enhanced cell proliferation and Matrigel invasion, indicating that FABP7 plays a role in the malignant phenotype of some melanoma cell lines. MMA1 down-regulation with MMA1 specific siRNAs suppressed in vitro cell proliferation and cell adhesion in melanoma cell lines. Over-expression of MMA1 in the melanoma cell lines with low MMA1 expression by transfecting with the MMA1 recombinant resulted in enhanced cell proliferation and adhesion, indicating that MMA1 also plays a role in the malignant phenotype of melanoma cells. Immunohistochemical examination revealed that FABP7 was expressed in 11 of 15 melanoma tissues. IgG Antibodies specific for the phage or bacterial recombinant FABP7 protein were detected in 14 of 25 (56%) or 8 of 31 (26%) sera from melanoma patients, respectively, but not in sera from healthy individuals, indicating that FABP7 is an immunogenic antigen in melanoma patients. These results demonstrated that FABP7 and MMA1 frequently expressed in melanoma may be potential targets for development of diagnostic and therapeutic methods.
识别在黑色素瘤细胞中优先表达并参与其恶性表型的分子对于理解黑色素瘤生物学和开发新的诊断和治疗方法是重要的。通过使用GeneChip比较黑素瘤细胞系与各种正常组织的表达谱,并通过RT-PCR确认所选基因的实际表达,我们鉴定了FABP 7、MMA 1和KU-MEL-3。通过RNA干扰和重组转导分析这些基因的功能。通过用FABP 7特异性siRNA下调FABP 7表达,在黑色素瘤细胞系中抑制体外细胞增殖和Matrigel侵袭。通过用FABP 7 cDNA转染在FABP 7阴性的胚肾细胞系293 T中过表达FABP 7,导致增强的细胞增殖和Matrigel侵袭,表明FABP 7在一些黑素瘤细胞系的恶性表型中起作用。MMA 1特异性siRNA下调MMA 1可抑制黑色素瘤细胞系的体外细胞增殖和细胞粘附。通过用MMA 1重组体转染,在具有低MMA 1表达的黑素瘤细胞系中MMA 1的过表达导致增强的细胞增殖和粘附,表明MMA 1在黑素瘤细胞的恶性表型中也起作用。免疫组化结果显示,FABP 7在15例黑色素瘤组织中有11例表达。分别在来自黑素瘤患者的25份血清中的14份(56%)或31份血清中的8份(26%)中检测到对噬菌体或细菌重组FABP 7蛋白特异性的IgG抗体,但在来自健康个体的血清中未检测到,表明FABP 7是黑素瘤患者中的免疫原性抗原。这些结果表明,FABP 7和MMA 1在黑色素瘤中频繁表达,可能是开发诊断和治疗方法的潜在靶点。

项目成果

期刊论文数量(18)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Systematic identification of human melanoma antigens using serial analysis of gene expression (SAGE)
  • DOI:
    10.1097/00002371-200501000-00002
  • 发表时间:
    2005-01-01
  • 期刊:
  • 影响因子:
    3.9
  • 作者:
    Matsuzaki, Y;Hashimoto, S;Kawakami, Y
  • 通讯作者:
    Kawakami, Y
A NOVEL MELANOMA ANTIGEN, FCRL/FREB, IDENTIFIED BY cDNA PROFILE COMPARISON USING DNA CHIP ARE IMMUNOGENIC IN MULTIPLE MELANOMA PATIENTS
使用 DNA 芯片通过 cDNA 图谱比较鉴定的新型黑色素瘤抗原 FCRL/FREB 在多种黑色素瘤患者中具有免疫原性
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Hiroshi Murata;et al.;Takashi Inozume et al.
  • 通讯作者:
    Takashi Inozume et al.
Novel melanoma antigen, FCRL/FREB, identified by cDNA profile comparison using DNA chip are immunogenic in multiple melanoma patients.
使用 DNA 芯片通过 cDNA 图谱比较鉴定出的新型黑色素瘤抗原 FCRL/FREB 在多种黑色素瘤患者中具有免疫原性。
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Inozume T;Matsuzaki Y;Kurihara S;Fujita T;Yamamoto A;Aburatani H;Shimada S;Kawakami Y
  • 通讯作者:
    Kawakami Y
Immunological detection of altered signaling molecules involved in melanoma development.
免疫学检测参与黑色素瘤发展的改变的信号分子。
Immune responses to DNA mismatch repair enzymes hMSH2 and hPMS1 in patients with pancreatic cancer, dermatomyositis and polymyositis
  • DOI:
    10.1002/ijc.21118
  • 发表时间:
    2005-10-10
  • 期刊:
  • 影响因子:
    6.4
  • 作者:
    Okada, T;Noji, S;Kawakami, Y
  • 通讯作者:
    Kawakami, Y
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MATSUZAKI Yuriko其他文献

MATSUZAKI Yuriko的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MATSUZAKI Yuriko', 18)}}的其他基金

Establishment of transgenic HRAS medaka as a tumor model for in vivo drug screening
转基因HRAS青鳉肿瘤模型的建立用于体内药物筛选
  • 批准号:
    24591633
  • 财政年份:
    2012
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
New melanoma model using transgenic medaka fish
使用转基因青鳉鱼的新黑色素瘤模型
  • 批准号:
    21591444
  • 财政年份:
    2009
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Functional analysis of molecules identified by comprehensive geneexpressive analysis for development of diagnosis and treatment ofmelanoma
通过综合基因表达分析鉴定的分子的功能分析,用于开发黑色素瘤的诊断和治疗
  • 批准号:
    19591327
  • 财政年份:
    2007
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigation of the function of genes expressed in melanoma/melanocyte with RNA interference for understanding of pigment disorders
通过 RNA 干扰研究黑色素瘤/黑色素细胞中表达的基因的功能,以了解色素障碍
  • 批准号:
    15591193
  • 财政年份:
    2003
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 2.24万
  • 项目类别:
Dual action immunostimulatory nanoparticles for treatment of aggressive cancers
用于治疗侵袭性癌症的双重作用免疫刺激纳米颗粒
  • 批准号:
    10618487
  • 财政年份:
    2023
  • 资助金额:
    $ 2.24万
  • 项目类别:
Immunomodulatory biomaterial to enhancing T-cell responses to triple negative breast cancer
免疫调节生物材料可增强 T 细胞对三阴性乳腺癌的反应
  • 批准号:
    10699815
  • 财政年份:
    2023
  • 资助金额:
    $ 2.24万
  • 项目类别:
Spatial Profiling of Melanocytic Tumors and Their Microenvironment
黑素细胞肿瘤及其微环境的空间分析
  • 批准号:
    10729434
  • 财政年份:
    2023
  • 资助金额:
    $ 2.24万
  • 项目类别:
Developing new therapeutic strategies for brain metastasis
开发脑转移的新治疗策略
  • 批准号:
    10578405
  • 财政年份:
    2023
  • 资助金额:
    $ 2.24万
  • 项目类别:
Role of AMPK in melanoma brain metastasis
AMPK 在黑色素瘤脑转移中的作用
  • 批准号:
    10927688
  • 财政年份:
    2023
  • 资助金额:
    $ 2.24万
  • 项目类别:
Investigating the epidermal microenvironment in melanoblast migration and invasion: a novel approach to understanding invasive melanoma
研究黑色素细胞迁移和侵袭的表皮微环境:一种了解侵袭性黑色素瘤的新方法
  • 批准号:
    10537221
  • 财政年份:
    2023
  • 资助金额:
    $ 2.24万
  • 项目类别:
Innate NLRC4 signaling controls adaptive immune responses
先天 NLRC4 信号控制适应性免疫反应
  • 批准号:
    10707832
  • 财政年份:
    2023
  • 资助金额:
    $ 2.24万
  • 项目类别:
Systems Biology of Antigen and T-Cell Transport in Cancer Immunotherapy
癌症免疫治疗中抗原和 T 细胞运输的系统生物学
  • 批准号:
    10751192
  • 财政年份:
    2023
  • 资助金额:
    $ 2.24万
  • 项目类别:
Role of AMPK in melanoma brain metastasis
AMPK 在黑色素瘤脑转移中的作用
  • 批准号:
    10567049
  • 财政年份:
    2023
  • 资助金额:
    $ 2.24万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了